肿瘤标志物CA19-9在恶性肿瘤诊断中的价值

Systematic analysis of tumor markers CA19-9 in serum and its clinical significance in cancer diagnosis

目的探讨多肿瘤标志物蛋白芯片法测定糖类抗原(CA19-9)在各组人群中阳性表达及其他肿瘤标志物伴随上升情况的临床意义。方法分析50670例多肿瘤蛋白芯片法测定结果。CA19-9在各人群阳性分布以及CA19-9阳性伴随其他肿瘤标志物在不同肿瘤、不同病理分型肺癌中阳性分布情况。结果 CA19-9在恶性肿瘤患者中显著升高且在胰腺癌中最高(61.77%),其次为肝癌(43.37%)、胃癌(40.26%)。CA19-9伴随其他肿瘤标志物CEA升高呈显著性。结论 CA19-9对胰腺癌诊断价值较大,而要提高恶性肿瘤临床诊断、疗效判断及病情监测,多肿瘤标志物联合应用价值显著。

Objective To investigate the serum level of CA19-9 and other indicators in different tumors and their clinical significance. Methods A total of 50 670 cases detected by multi-tumor protein chip in our hospital were collected and analyzed. The positive rate of CA19-9 with other accompanied indicators was analyzed in different tumors as well as lung cancer of different pathological types. Results The serum level of CA19-9 was markedly higher in malignant tumors. The positive rate of CA19-9 was the highest in pancreatic cancer （61.77%） and then in liver cancer （43.37 % ）, and gastric cancer （40.26 % ）. CEA was the most common indicator accompan- ying the up-expression of CA19-9. Conclusion The elevation of CA19-9 is significant in the diagnosis of pancreatic cancer. When detected in combination with multiple tumor markers, it is the most effective marker in the diagnosis and therapeutic effect monitoring of malignant tumors.